Molecular Weight(MW): 463.48
Dibenzazepine (YO-01027) is a dipeptidic γ-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM in cell-free assays for APPL and Notch cleavage, respectively.
Cited by 12 Publications
4 Customer Reviews
Tumor spheres formation assay. Images were taken at 48 h after treating the cells with various formulations of YO (scale bar 100 um).
Journal of Pharmaceutical Investigation 2014 10.1007/s40005-014-0151-2. Dibenzazepine (YO-01027) purchased from Selleck.
NSG mice were engrafted with human DND41 cells in 3 independent experiments. After DBZ treatment, marrow leukemia burden was determined by the expression of human CD45 (hCD45). Host LSK (hCD45−) (A), OB (B) and MSC frequencies (C) were determined by FACS in control (receiving culture medium) or in xenografted mice treated with vehicle or DBZ (n=8–9.group).
Cancer Res, 2016, 76(6):1641-52. Dibenzazepine (YO-01027) purchased from Selleck.
Inhibition of Notch signaling by dibenzazepine (DBZ) leads to decreased cell proliferation and secretory cell hyperplasia. The intestine isolated from stage‐56/57 tadpoles was cultured with 20 nM T3 for 5 (A-F) or 7 (G-J) days in the presence of DMSO (A, C, E, G, I) or 10 μM DBZ (B, D, F, H, J) after precultivation of the isolated intestinal fragments with DMSO or 10 μM DBZ for 3 days (see Fig. Fig.4A).4A). Cryosections of the intestinal fragments were hybridized with antisense Hairy1 (A, B) or Hairy2b (C, D). Paraffin sections were incubated with anti‐PCNA (E, F) or anti-IFABP (G, H) antibodies or subjected to Periodic acid‐Schiff (PAS) staining followed by counter-staining with hematoxylin (I, J). As a control, paraffin sections of the intestine from wild type froglets at stage 66 were also stained with PAS to identify goblet cells (K, arrowheads). Note that after 5 days, TH‐induced up‐regulation of Hairy genes (A, C, arrowheads) was impaired by DBZ treatment in vitro (B, D). PCNA‐positive epithelial cells also decreased by DBZ treatment (E, F, arrowheads). After 7 days, IFABP was detected in most of the newly formed adult epithelial cells of the control intestine (G, arrowheads), but not the DBZ-treated intestine (H). A small number of goblet cell was detected in the control intestine (I, arrowhead), whereas PAS-positive secretory cells increased by DBZ treatment (J, arrowheads). The dashed-lines indicate the boundary of the epithelium and the connective tissue. Scale bars = 20 μm. Abbreviations: CT, connective tissue, DBZ, dibenzazepine, Ep, epithelium, PAS, Periodic acid‐Schiff.
Stem Cells, 2017, 35(4):1028-1039. Dibenzazepine (YO-01027) purchased from Selleck.
Overexpression of PrP enhances Notch1 signaling and cancer cell growth and invasion. Capan-1 cells were transfected with control or PrP-expressing plasmid. A: Expression of PrP, Notch1, and Hes1 was assessed by immunoblotting. N1 and Hes1 expression was also assessed after DBZ treatment (20 μmol/L for 48 hours) (right two columns). B and C: PrP-OE increases cell growth (B) and migration (C), although DBZ treatment decelerates Capan-1 proliferation and migration. D: Control or PrP-OE Capan-1 cells were injected ipsilaterally on the back of nude mice. Paired animals received either PBS (control or PrP-OE) or DBZ (control + DBZ or PrP-OE + DBZ) for 3 consecutive days every 7 days. Tumors were dissected at the end of 6 weeks. Tumor volumes were measured weekly and at the end of experiments. Data are expressed as means ± SD. t-test was performed (B–D). n = 3 independent experiments (A); n = 6 mice (B and C); n = 8 biological replicates (B and C); n = 5 mice in each group (D). ∗P < 0.05, ∗∗P < 0.01. Ctrl, control; DBZ, dibenzazepine; N1, Notch1; OE, overexpression; PBS, phosphate-buffered saline; PrP, prion protein.
Am J Pathol, 2016, 186(11):2945-2956. Dibenzazepine (YO-01027) purchased from Selleck.
Purity & Quality Control
Choose Selective Gamma-secretase Inhibitors
|Description||Dibenzazepine (YO-01027) is a dipeptidic γ-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM in cell-free assays for APPL and Notch cleavage, respectively.|
YO-01027 interacts directly with theγ-secretase complex and targets the N-terminal Presenilin fragment. Increasing concentrations of YO-01027 administered to APPL- or Notch-expressing cells leads to the progressive accumulation of APPL CTF fragments and a decrease in NICD production in a strictly dose-dependent manner.  10 μM of YO-01027 reduces breast cancer stem cells (BCSC) number and activity.  A recent research indicates YO-01027 impairs mucin protein MUC16 biosynthesis in a concentration-dependent manner in undifferentiated cells at both preconfluent and confluent stages through Notch inhibition, but not in postmitotic stratified cells. 
|In vivo||YO-01027, which is delivered 1 mg/mL by i.p. injection on the day of cell injection and every subsequent 3 days, YO-01027 significantly, decreases MCF7 but not MDA-MB-231 tumors and increases latency compared with control mice (18-28 days). YO-01027-treated MCF7 tumors that did form had significantly reduced tumor volumes.  Treatment of YO-01027 into C57BL/6 mice inhibits epithelial cell proliferation and induces goblet cell differentiation in intestinal adenomas in a dose-dependent manner. |
Pharmacological Inhibition of γ-secretase Activity:For YO-01027, pilot experiments are performed with different drug concentrations ranging from 0.1 nM to 250 nM to determine the effective linear range and maximal inhibition dose for YO-01027. YO-01027 is added at the required concentrations to the S2 cell medium upon induction of Notch or APPL expression, 6 hours before protein harvesting. For each sample, YO-01027 is also included at the corresponding concentration in the lysis buffer for protein extraction and immunoblot analysis.
|In vitro||DMSO||92 mg/mL (198.49 mM)|
|In vivo||Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% hydroxyethyl cellulose
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Frequently Asked Questions
How to dissolve the compund for in vivo applications?
For S2711, we suggest to use 0.5% hydroxyethyl cellulose in vivo study.